The Hospital for Special Surgery (HSS) located in Manhattan is ranked as the #1 hospital for orthopedics by the prestigious US News and World Report (2016-2017). And when the surgeons and clinicians at this elite medical institution need to make a proper foot and ankle diagnosis, they rely on CurveBeam’s revolutionary pedCAT system for fast and accurate 3D imaging.
Assessing the root cause of a patient’s pain is essential for developing a comprehensive treatment plan. At HSS, this evaluation process begins with an interview so that specialists can learn a patient’s unique history and obtain information regarding the primary care physician’s prognosis. Then the patient steps into the pedCAT scanner, where expert radiologists can conduct foot and ankle imaging faster than X-rays and CT scans, resulting in fewer hospital trips and significantly reduced exposure to radiation. The pedCAT system delivers the highest quality images and robust data, allowing physicians to make the most accurate diagnosis of the malady, and guiding the surgeon in the operating room for a superior treatment outcome. Watch below and visit curvebeam.com to learn more about the pedCAT.
The deal made headlines in the orthopedic community when Stryker, one of the world’s largest medical technology companies, acquired MAKO Surgical Corp., in December 2013. MAKO pioneered the advancement of the robotic arm to assist in hip and knee orthopedic surgeries.
A post-script of an Orthopedics This Week podcast on the subject, the author noted:
“One re-occurring questions from surgeons, who are all dealing with the realities of an increasingly cost conscious health care system, is why would Stryker acquire a company which sells million dollar robots in this period of health care cost reduction?”
We often hear similar feedback from physicians who say they cannot justify a pedCAT purchase when major changes to healthcare loom ahead. Our response is that now more than ever, definitive diagnoses, accurate pre-surgical plans, and comprehensive post-surgical evaluations are crucial. The new medical landscape demands more efficient care.
It seems Stryker agrees. It’s response, as reported by Orthopedics This Week:
“Stryker’s answer is that MAKO will simplify joint reconstruction procedures, reduce variability, and enhance the surgeon and patient experience. And in dollar terms, Stryker’s implants comprise about 80 percent the total cost of large joint replacement. The rest of the cost of surgery is everything else including the surgery itself, rehab, and any problems that come up. Small gains in the non-implant portion of surgery, like fewer errors, more consistent outcomes, can have a huge effect on overall costs. At a time when insurance companies are asking hospitals, surgeons and implant suppliers to virtually guarantee outcomes and eliminate variability, Stryker’s purchase of MAKO is a $1.65 billion bet that robots are the answer.”